 Multiple Sclerosis, Relapsing-Remitting
"Multiple Sclerosis, Relapsing-Remitting" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
| Descriptor ID |
D020529
|
| MeSH Number(s) |
C10.114.375.500.600 C10.314.350.500.600 C20.111.258.250.500.600
|
| Concept/Terms |
Multiple Sclerosis, Relapsing-Remitting- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Relapsing Remitting
- Remitting-Relapsing Multiple Sclerosis
- Multiple Sclerosis, Remitting-Relapsing
- Remitting Relapsing Multiple Sclerosis
- Relapsing-Remitting Multiple Sclerosis
- Relapsing Remitting Multiple Sclerosis
|
Below are MeSH descriptors whose meaning is more general than "Multiple Sclerosis, Relapsing-Remitting".
Below are MeSH descriptors whose meaning is more specific than "Multiple Sclerosis, Relapsing-Remitting".
This graph shows the total number of publications written about "Multiple Sclerosis, Relapsing-Remitting" by people in this website by year, and whether "Multiple Sclerosis, Relapsing-Remitting" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 | | 2001 | 3 | 0 | 3 | | 2003 | 1 | 0 | 1 | | 2004 | 6 | 0 | 6 | | 2005 | 2 | 0 | 2 | | 2006 | 1 | 0 | 1 | | 2007 | 1 | 2 | 3 | | 2008 | 4 | 1 | 5 | | 2009 | 3 | 0 | 3 | | 2010 | 2 | 1 | 3 | | 2011 | 3 | 1 | 4 | | 2012 | 3 | 0 | 3 | | 2013 | 3 | 0 | 3 | | 2014 | 2 | 0 | 2 | | 2015 | 8 | 0 | 8 | | 2016 | 5 | 0 | 5 | | 2017 | 4 | 0 | 4 | | 2018 | 3 | 0 | 3 | | 2019 | 3 | 0 | 3 | | 2020 | 3 | 0 | 3 | | 2021 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Multiple Sclerosis, Relapsing-Remitting" by people in Profiles.
-
Aktas O, Smith MA, Rees WA, Bennett JL, She D, Katz E, Cree BAC. Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. Ann Neurol. 2021 05; 89(5):895-910.
-
Sánchez-Fernández A, Zandee S, Amo-Aparicio J, Charabati M, Prat A, Garlanda C, Eisenmesser EZ, Dinarello CA, López-Vales R. IL-37 exerts therapeutic effects in experimental autoimmune encephalomyelitis through the receptor complex IL-1R5/IL-1R8. Theranostics. 2021; 11(1):1-13.
-
Hartung HP, Berger T, Bermel RA, Brochet B, Carroll WM, Holmøy T, Karabudak R, Killestein J, Nos C, Patti F, Ross AP, Vanopdenbosch L, Vollmer T, Buffels R, Garas M, Kadner K, Manfrini M, Wang Q, Freedman MS. Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2020 Nov; 46:102492.
-
Davis LA, Alenazy MS, Almuklass AM, Feeney DF, Vieira T, Botter A, Enoka RM. Force control during submaximal isometric contractions is associated with walking performance in persons with multiple sclerosis. J Neurophysiol. 2020 06 01; 123(6):2191-2200.
-
Rempe T, Wang Q, Wu Q, Ballur Narayana Reddy V, Newcomer Z, Miravalle A, Mao-Draayer Y. Progressive multifocal leukoencephalopathy and granule cell neuronopathy with novel mutation flanking VP1 C-terminus in natalizumab-extended interval dosing. Neurol Neuroimmunol Neuroinflamm. 2020 05 04; 7(3).
-
Vollmer B, Ontaneda D, Harris H, Nair K, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. J Neurol Sci. 2019 Dec 15; 407:116498.
-
Lovett-Racke AE, Gormley M, Liu Y, Yang Y, Graham C, Wray S, Racke MK, Shubin R, Twyman C, Alvarez E, Bass A, Eubanks JL, Fox E. B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients. J Neuroimmunol. 2019 07 15; 332:187-197.
-
Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology. 2019 02 12; 92(7):e723-e732.
-
Evan JR, Bozkurt SB, Thomas NC, Bagnato F. Alemtuzumab for the treatment of multiple sclerosis. Expert Opin Biol Ther. 2018 03; 18(3):323-334.
-
Almuklass AM, Davis L, Hamilton LD, Hebert JR, Alvarez E, Enoka RM. Pulse Width Does Not Influence the Gains Achieved With Neuromuscular Electrical Stimulation in People With Multiple Sclerosis: Double-Blind, Randomized Trial. Neurorehabil Neural Repair. 2018 01; 32(1):84-93.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|